Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabizabulin +/- Sacituzumab Govitecan in mTNBC
NCT05008510Phase 2Withdrawn
- Sponsor
- Veru Inc.
- Start
- Dec 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of sabizabulin in triple negative breast cancer (TNBC), sponsored by Veru Inc.. Planned start Dec 2021; status: withdrawn.
02
Drugs
sabizabulin
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05008510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05008510.